Opus Genetics (NASDAQ:IRD) COO Joseph Schachle Sells 3,719 Shares

Opus Genetics, Inc. (NASDAQ:IRD) COO Joseph Schachle sold 3,719 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $5.25, for a total value of $19,524.75. Following the sale, the chief operating officer owned 300,781 shares of the company’s stock, valued at $1,579,100.25. This represents a 1.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Opus Genetics Trading Down 4.0%

IRD traded down $0.19 on Thursday, hitting $4.48. 327,179 shares of the company’s stock traded hands, compared to its average volume of 993,493. The company’s 50 day simple moving average is $3.35 and its 200-day simple moving average is $2.41. Opus Genetics, Inc. has a one year low of $0.65 and a one year high of $5.30. The firm has a market cap of $318.40 million, a price-to-earnings ratio of -5.41 and a beta of 0.45.

More Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Multiple analysts initiated/raised coverage with bullish ratings and higher price targets (Oppenheimer started coverage with an “outperform” and $10 target; Wedbush and BTIG recently raised targets and maintained buy/outperform views), giving the stock upside potential versus current levels. Article Title
• Neutral Sentiment: Institutional ownership movements show recent inflows from several funds (BIOS Capital, Voss Capital, Wells Fargo, State Street increased positions), which may support longer-term demand but have unclear timing impact on the share price. Article Title
• Neutral Sentiment: Liquidity and technicals: today’s volume is below the stock’s average (indicating lower trading interest), while the 50-day ($3.35) and 200-day ($2.41) moving averages and the 12‑month range ($0.65–$5.30) provide context for support/resistance levels. Article Title
• Negative Sentiment: Cluster of insider selling on March 16 — CEO George Magrath sold 24,438 shares (~$127k at ~$5.21), Ashwath Jayagopal sold 3,719 shares, COO Joseph K. Schachle sold 3,719 shares, and Amy Zaremba Rabourn sold 2,816 shares. These disclosures (filed with the SEC) represent modest reductions in insider stakes and are likely a principal driver of near-term downward pressure on the stock. Insider Trades CEO Form 4

Institutional Investors Weigh In On Opus Genetics

Large investors have recently bought and sold shares of the business. Occudo Quantitative Strategies LP bought a new position in Opus Genetics during the fourth quarter valued at $25,000. Comerica Bank bought a new stake in shares of Opus Genetics in the 1st quarter worth about $29,000. Virtu Financial LLC bought a new stake in shares of Opus Genetics in the 4th quarter worth about $34,000. Raymond James Financial Inc. raised its position in shares of Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after buying an additional 11,000 shares in the last quarter. Finally, Johnson Investment Counsel Inc. purchased a new stake in shares of Opus Genetics during the 4th quarter valued at about $40,000. Institutional investors own 14.97% of the company’s stock.

Analysts Set New Price Targets

IRD has been the subject of a number of research reports. Piper Sandler began coverage on shares of Opus Genetics in a research report on Tuesday, November 25th. They set an “overweight” rating and a $7.00 target price for the company. Lifesci Capital upgraded shares of Opus Genetics to a “strong-buy” rating in a research note on Thursday, February 12th. Craig Hallum set a $9.00 price objective on shares of Opus Genetics and gave the company a “buy” rating in a report on Wednesday, March 11th. Chardan Capital raised their price objective on Opus Genetics from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. Finally, raised Opus Genetics to a “strong-buy” rating in a report on Monday, December 1st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.33.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.